Added to YB: 2026-04-28
Pitch date: 2026-04-24
MEDP [neutral]
Medpace Holdings, Inc.
+1.47%
current return
Author Info
Expanse Stocks is a research-driven newsletter on equities & long-term investing. Sign up for the newsletter.
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Market Cap
$11.7B
Pitch Price
$415.28
Price Target
N/A
Dividend
N/A
EV/EBITDA
17.68
P/E
25.82
EV/Sales
4.19
Sector
Life Sciences Tools and Services
Category
growth
Medpace: Q1 2026
MEDP (earnings): Q1 rev $706.6M (+26.5% YoY), backlog conversion 23.3% vs 19.2% YoY. 0.88x book-to-bill driven by clinical trial failures (not funding issues) & high conversion inflating denominator. Metabolic now 31% rev (vs 23% prior, lowest cancellation rate) displacing Oncology (29%). 21.1% EBITDA margin, 97.1% FCF conversion. FY26 guide 8.9-12.8% rev growth unchanged. $652M cash, $800M+ buyback authorization unused. Hiring +6.3% YoY signals mgmt confidence despite soft awards.
Read full article (8 min)